Critical Therapeutics Will Use Tripos' LeadHopping Technology To Identify New Target Compounds
Tripos, Inc. announced a collaboration with Critical Therapeutics, Inc. (CTI), a privately held biopharmaceutical company discovering and developing novel therapies for critical-care medicine. Under the agreement, Tripos will identify and optimize small-molecule agonists for CTI's development program targeting a nicotinic acetylcholine receptor. By targeting this receptor, CTI intends to further the development of potential anti-inflammatory therapeutics.
Tripos will use its proprietary chemistry and discovery research processes, including its LeadQuest® chemical compound libraries and ChemSpace®-enabled LeadFocusSM and LeadHoppingSM programs, to select and synthesize compounds against CTI's target. Tripos will receive research payments and additional payments for successful achievement of agreed milestones.
Critical Therapeutics will begin this relationship by screening compounds selected by Tripos from the extensive LeadQuest database of "off-the-shelf" compounds. Tripos will use its proprietary ChemSpace design software to simultaneously perform topomer (shape and pharmacophore) searches of its more than 50 trillion-compound virtual libraries. This LeadHopping technique facilitates identification of synthetically accessible compounds that are shape-similar, structurally distinct and have different chemistries from the original lead compound. Rapid synthesis and biological testing follow the identification of potential lead compounds, thus minimizing project timelines.
Tripos and CTI expect that their combined efforts will enable the rapid identification of a novel, patentable lead series and ultimately will result in a new anti-inflammatory agent being brought into the clinic.
Most read news
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.

Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.